MHLW (Japan) approves Beyfortus (nirsevimab) in Japan for the prevention of RSV disease in infants – AstraZeneca
AstraZeneca and Sanofi’s Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus… read more.